Argos Therapeutics

Argos Therapeutics, Inc. is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells - the master switch that turns the immune system on or off.

Company Growth (employees)
Durham, US
Size (employees)
136 (est)
Argos Therapeutics was founded in 1997 and is headquartered in Durham, US

Argos Therapeutics Office Locations

Argos Therapeutics has an office in Durham
Durham, US (HQ)
4233 Technology Dr

Argos Therapeutics Metrics

Argos Therapeutics Financial Metrics

Argos Therapeutics's revenue was reported to be $945.5 k in FY, 2016 which is a 82% increase from the previous period.

Revenue (FY, 2016)

$945.5 k

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

($53 m)

EBIT (FY, 2016)

($52.3 m)

Market capitalization (22-May-2017)

$18 m

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$53 m
Argos Therapeutics's current market capitalization is $18 m.
FY, 2014FY, 2015FY, 2016


$2 m$518.3 k$945.5 k

Revenue growth, %


R&D expense

$45.5 m$62.1 m$38.3 m

General and administrative expense

$8.6 m$11 m$14.2 m

Operating expense total

$54.1 m$73.1 m$53.3 m


($52.1 m)($72.5 m)($52.3 m)

EBIT margin, %


Interest expense

($1.1 m)($2.3 m)($1.8 m)

Interest income

$66.6 k$25.4 k$57.3 k

Net Income

($53.3 m)($74.8 m)($53 m)
FY, 2014FY, 2015FY, 2016


$37.2 m$6.2 m$53 m

Accounts Receivable

$129 k$73.8 k$136.1 k

Current Assets

$57.5 m$8.8 m$55.5 m


$5.5 m$22.3 m$41 m

Total Assets

$64.4 m$31.1 m$97.2 m

Accounts Payable

$1.9 m$2.9 m$5.4 m

Current Liabilities

$3.3 m$8.2 m$30.6 m

Additional Paid-in Capital

$235.6 m$250.9 m$338.2 m

Retained Earnings

($204.2 m)($279 m)($332 m)

Total Equity

($28.2 m)

Financial Leverage

-1.1 x
FY, 2014FY, 2015FY, 2016

Net Income

($53.3 m)($74.8 m)($53 m)

Depreciation and Amortization

$566.1 k$680.4 k$952.3 k

Accounts Receivable

($252 k)($629 k)($906 k)

Accounts Payable

$543.4 k($137 k)$1.2 m

Cash From Operating Activities

$3.9 m($31.1 m)($40.7 m)

Purchases of PP&E

($1.1 m)($9.7 m)($15.3 m)

Cash From Investing Activities

($7.8 m)$8.9 m($14.3 m)

Long-term Borrowings

($51.5 k)($35.5 k)($1.6 m)

Cash From Financing Activities

$57 m$21.1 m$101.8 m

Interest Paid

$307.9 k$1.6 m$2.4 m

Argos Therapeutics Market Value History

Argos Therapeutics Online Presence

Argos Therapeutics Company Life

You may also be interested in